MMP9 and Stroke: Olmesartan, a AT1 receptor blocker can reduce the reactive upregulation in brain angiotensin II, MMP-2, MMP-9 and membrane type 1-MMP in the ischemic area to improve stroke index score, infarct volume, and cerebral edema in cerebral ischemia model.